Kodiak Sciences surged 178% following positive Phase III trial updates for a wet age-related macular degeneration treatment. Lifecore Biomedical rose 55% after agreeing to a $663.7 million acquisition by Webster Equity Partners. YD Bio gained 22%, likely boosted by short-squeeze activity amid rising short interest. These gains highlight how clinical progress, acquisition news, and trading dynamics can drive significant stock moves.
The recent top stock gains including Kodiak Sciences, Lifecore Biomedical, and YD Bio provide context for health-sector trading on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Sep 29, 2026 04:11 WIB: out of 100 priced health-sector US stocks, 52 rose and 47 fell. Among notable movers, ClearPoint Neuro Inc (CLPT) increased by 2.70% with a typical hold time of 10 days and 100% buy order activity, contrasting with Teladoc Health Inc (TDOC) and TransMedics Group Inc (TMDX), which both declined by around 3% and had longer hold times and predominantly sell order activity for TMDX.
Several high-volume stocks including ITG Inc, Adicet Bio, Jaguar Health, Ocular Therapeutix, and Greenland Mines experienced sharp declines despite recent positive company news. The drops, ranging from about 19% to over 32%, appear driven by profit-t...
Lifecore Biomedical's stock surged 55.24% to $6.52 after announcing an acquisition by Webster Equity Partners offering $6.28 per share in cash plus potential Contingent Value Rights up to $9.67 per share. The deal values the company at up to $663.7 m...
A director of Espey Manufacturing and Electronics Corp sold 100 shares at $64.49 each, reducing his holdings to 20,550 shares. This insider sale happened after the company reported strong 2026 financial results, including net sales growth to $46.1 mi...
Vail Resorts reported Q4 earnings per share of -$5.34, slightly better than expected, with revenue of $278.1 million surpassing estimates. The company benefited from a 5.2% rise in mountain revenues, driven by strong pass sales in Australia and stabl...
Conagra Brands is set to report Q1 earnings with analysts forecasting a 1.4% revenue decline to about $2.59 billion due to weak consumer spending and inflation. Earnings per share are expected to drop 20.5% to $0.31, reflecting margin pressures and a...
